The FDA has approved Cobenfy (BMS), an oral fixed-dose combination of the muscarinic agonist xanomeline and the peripheral muscarinic antagonist trospium chloride, for treatment of schizophrenia in adults. It is the first antipsychotic drug to be approved in the US for treatment of schizophrenia that does not block dopamine receptors. This is the first approval for xanomeline; trospium has been available for many years for treatment of overactive bladder.
STANDARD TREATMENT — Drugs that target dopamine receptors are the standard of care for treatment of schizophrenia; second-generation...
- Lebrikizumab (Ebglyss) for Atopic Dermatitis
- Eroxon — An OTC Gel for Erectile Dysfunction
- Risankizumab (Skyrizi) for Ulcerative Colitis
- Axatilimab (Niktimvo) for Chronic Graft-Versus-Host Disease (online only)
- Inavolisib (Itovebi) for Locally Advanced or Metastatic Breast Cancer (online only)
- Vorasidenib (Voranigo) for Low-Grade Glioma (online only)
- In Brief: A New Non-Small Cell Lung Cancer Indication for Osimertinib (Tagrisso) (online only)
- Drugs for Hepatitis C Virus Infection
- In Brief: Subcutaneous Ocrelizumab (Ocrevus Zunovo) for Multiple Sclerosis
- In Brief: FluMist Influenza Vaccine for Self-Administration
- COVID-19 Update: Novavax Vaccine for 2024-2025
- Figure 1: Treatment of Hepatitis C Virus Infection in Treatment-Naive Adults (online only)
- Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)
- Lazertinib (Lazcluze) for Non-Small Cell Lung Cancer (online only)
RELEASE
The FDA has approved Onyda XR (Tris), an extended-release (ER) oral suspension formulation of the alpha2-adrenergic agonist clonidine, for use as monotherapy or as an adjunct to stimulant therapy for treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥6 years old. Clonidine ER tablets have been available for years for treatment of ADHD in children 6-17 years old.
STANDARD TREATMENT — Stimulants such as amphetamines and methylphenidate are the drugs of choice for treatment of ADHD. They are classified as schedule II controlled substances. The alpha2-agonists clonidine and guanfacine (Intuniv, and generics) and the selective norepinephrine reuptake inhibitors atomoxetine (Strattera, and generics) and viloxazine (Qelbree), which are not controlled substances, can …